In combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.
In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
No medicines have been found.
